A real-world study of over 4,000 US patients without type 2 diabetes found that those who persisted with Tirzepatide for at ...

Experts stress that obesity is a disease, not a lifestyle choice, and call for better access to pharmacological and surgical ...

Obesity is a common health problem affecting a considerable (and growing) proportion of adult populations worldwide.1 Although overweight and obesity are usually diagnosed by anthropometry, such as ...

The pharmaceutical industry is not stopping there. There are already 100 new drug candidates in trials, all vying for a slice ...

Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.

The Outsourcing Facilities Association is appealing a ruling that rejected their request for an injunction against the FDA’s ...

A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture ...

Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market ...

Researchers analysed data from 150 adults with T1D, divided into semaglutide, tirzepatide, and control groups.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced presentation of preclinical data supporting the advancement of ...

These findings suggest a potential new therapeutic approach for improving glycemic control and addressing obesity in T1D ... divided into semaglutide, tirzepatide, and control groups.